Whole-Body [18F]FDG-PET/MRI vs. [18F]FDG-PET/CT in Malignant Melanoma

Dominik Berzaczy; Barbara Fueger; Christoph Hoeller; Alexander R Haug; Anton Staudenherz; Gundula Berzaczy; Michael Weber; Marius E Mayerhoefer

doi:10.1007/s11307-019-01413-7

Whole-Body [18F]FDG-PET/MRI vs. [18F]FDG-PET/CT in Malignant Melanoma

Dominik Berzaczy, Barbara Fueger, Christoph Hoeller, Alexander R Haug, Anton Staudenherz, Gundula Berzaczy, Michael Weber, Marius E Mayerhoefer

Institute of Nuclear Medicine, Molecular Imaging and Special Endocrinology (University Hospital St. Pölten)

Research output: Journal article (peer-reviewed) › Journal article

11 Citations (Scopus)

Abstract

PURPOSE: To assess the diagnostic performance of simultaneous whole-body 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) compared to [18F]FDG PET/x-ray computed tomography (CT) for detection of distant metastatic disease in patients with malignant melanoma.

PROCEDURES: We included patients with malignant melanoma who underwent a single injection [18F]FDG dual-imaging protocol that included whole-body PET/CT and subsequent whole-body PET/MRI for staging or restaging purposes in a prospective setting. Images from both modalities were analyzed by two rater teams for the presence of metastatic lesions. PET/CT-PET/MRI overall agreement as well as region-based accuracies, sensitivities (Se), and specificities (Sp) were computed.

RESULTS: Between July 2014 and December 2018, 22 patients were enrolled. Interrater agreement and overall accuracy (consensus reading) were 78.8 % (95 % CI 71-84.9) and 96.1 % (95 % CI 92.3-98) for PET/MRI and 78 % (70.2-84.3) and 97.4 % (95 % CI 93.7-98.9) for PET/CT, respectively (P = 0.42). PET/MRI reached a region-based Se of 89.1 % (95 % CI 79.4-94.5) and a Sp of 100 %, whereas PET/CT showed a region-based Se of 92.7 % (95 % CI 84-96.9) and a Sp of 100 % for the detection of metastatic disease in malignant melanoma.

CONCLUSIONS: Whole-body [18F]FDG-PET/MRI appears to be comparable to [18F]FDG-PET/CT for lesion detection in patients with malignant melanoma.

Original language	English
Pages (from-to)	739-744
Number of pages	6
Journal	Molecular Imaging and Biology
Volume	22
Issue number	3
DOIs	https://doi.org/10.1007/s11307-019-01413-7
Publication status	Published - 01 Jun 2020

Keywords

Female
Fluorodeoxyglucose F18/chemistry
Humans
Magnetic Resonance Imaging/methods
Male
Melanoma/diagnostic imaging
Middle Aged
Multimodal Imaging/methods
Neoplasm Metastasis
Positron Emission Tomography Computed Tomography/methods
Positron-Emission Tomography/methods
Prospective Studies
Radiopharmaceuticals/chemistry
Whole Body Imaging/methods

Access to Document

10.1007/s11307-019-01413-7

Cite this

@article{65278bfd4acf474ba03f09d0a24a1f89,

title = "Whole-Body [18F]FDG-PET/MRI vs. [18F]FDG-PET/CT in Malignant Melanoma",

abstract = "PURPOSE: To assess the diagnostic performance of simultaneous whole-body 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) compared to [18F]FDG PET/x-ray computed tomography (CT) for detection of distant metastatic disease in patients with malignant melanoma.PROCEDURES: We included patients with malignant melanoma who underwent a single injection [18F]FDG dual-imaging protocol that included whole-body PET/CT and subsequent whole-body PET/MRI for staging or restaging purposes in a prospective setting. Images from both modalities were analyzed by two rater teams for the presence of metastatic lesions. PET/CT-PET/MRI overall agreement as well as region-based accuracies, sensitivities (Se), and specificities (Sp) were computed.RESULTS: Between July 2014 and December 2018, 22 patients were enrolled. Interrater agreement and overall accuracy (consensus reading) were 78.8 % (95 % CI 71-84.9) and 96.1 % (95 % CI 92.3-98) for PET/MRI and 78 % (70.2-84.3) and 97.4 % (95 % CI 93.7-98.9) for PET/CT, respectively (P = 0.42). PET/MRI reached a region-based Se of 89.1 % (95 % CI 79.4-94.5) and a Sp of 100 %, whereas PET/CT showed a region-based Se of 92.7 % (95 % CI 84-96.9) and a Sp of 100 % for the detection of metastatic disease in malignant melanoma.CONCLUSIONS: Whole-body [18F]FDG-PET/MRI appears to be comparable to [18F]FDG-PET/CT for lesion detection in patients with malignant melanoma.",

keywords = "Female, Fluorodeoxyglucose F18/chemistry, Humans, Magnetic Resonance Imaging/methods, Male, Melanoma/diagnostic imaging, Middle Aged, Multimodal Imaging/methods, Neoplasm Metastasis, Positron Emission Tomography Computed Tomography/methods, Positron-Emission Tomography/methods, Prospective Studies, Radiopharmaceuticals/chemistry, Whole Body Imaging/methods",

author = "Dominik Berzaczy and Barbara Fueger and Christoph Hoeller and Haug, {Alexander R} and Anton Staudenherz and Gundula Berzaczy and Michael Weber and Mayerhoefer, {Marius E}",

note = "Publisher Copyright: {\textcopyright} 2019, World Molecular Imaging Society.",

year = "2020",

month = jun,

day = "1",

doi = "10.1007/s11307-019-01413-7",

language = "English",

volume = "22",

pages = "739--744",

journal = "Molecular Imaging and Biology",

issn = "1536-1632",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

TY - JOUR

T1 - Whole-Body [18F]FDG-PET/MRI vs. [18F]FDG-PET/CT in Malignant Melanoma

AU - Berzaczy, Dominik

AU - Fueger, Barbara

AU - Hoeller, Christoph

AU - Haug, Alexander R

AU - Staudenherz, Anton

AU - Berzaczy, Gundula

AU - Weber, Michael

AU - Mayerhoefer, Marius E

PY - 2020/6/1

Y1 - 2020/6/1

N2 - PURPOSE: To assess the diagnostic performance of simultaneous whole-body 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) compared to [18F]FDG PET/x-ray computed tomography (CT) for detection of distant metastatic disease in patients with malignant melanoma.PROCEDURES: We included patients with malignant melanoma who underwent a single injection [18F]FDG dual-imaging protocol that included whole-body PET/CT and subsequent whole-body PET/MRI for staging or restaging purposes in a prospective setting. Images from both modalities were analyzed by two rater teams for the presence of metastatic lesions. PET/CT-PET/MRI overall agreement as well as region-based accuracies, sensitivities (Se), and specificities (Sp) were computed.RESULTS: Between July 2014 and December 2018, 22 patients were enrolled. Interrater agreement and overall accuracy (consensus reading) were 78.8 % (95 % CI 71-84.9) and 96.1 % (95 % CI 92.3-98) for PET/MRI and 78 % (70.2-84.3) and 97.4 % (95 % CI 93.7-98.9) for PET/CT, respectively (P = 0.42). PET/MRI reached a region-based Se of 89.1 % (95 % CI 79.4-94.5) and a Sp of 100 %, whereas PET/CT showed a region-based Se of 92.7 % (95 % CI 84-96.9) and a Sp of 100 % for the detection of metastatic disease in malignant melanoma.CONCLUSIONS: Whole-body [18F]FDG-PET/MRI appears to be comparable to [18F]FDG-PET/CT for lesion detection in patients with malignant melanoma.

AB - PURPOSE: To assess the diagnostic performance of simultaneous whole-body 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) compared to [18F]FDG PET/x-ray computed tomography (CT) for detection of distant metastatic disease in patients with malignant melanoma.PROCEDURES: We included patients with malignant melanoma who underwent a single injection [18F]FDG dual-imaging protocol that included whole-body PET/CT and subsequent whole-body PET/MRI for staging or restaging purposes in a prospective setting. Images from both modalities were analyzed by two rater teams for the presence of metastatic lesions. PET/CT-PET/MRI overall agreement as well as region-based accuracies, sensitivities (Se), and specificities (Sp) were computed.RESULTS: Between July 2014 and December 2018, 22 patients were enrolled. Interrater agreement and overall accuracy (consensus reading) were 78.8 % (95 % CI 71-84.9) and 96.1 % (95 % CI 92.3-98) for PET/MRI and 78 % (70.2-84.3) and 97.4 % (95 % CI 93.7-98.9) for PET/CT, respectively (P = 0.42). PET/MRI reached a region-based Se of 89.1 % (95 % CI 79.4-94.5) and a Sp of 100 %, whereas PET/CT showed a region-based Se of 92.7 % (95 % CI 84-96.9) and a Sp of 100 % for the detection of metastatic disease in malignant melanoma.CONCLUSIONS: Whole-body [18F]FDG-PET/MRI appears to be comparable to [18F]FDG-PET/CT for lesion detection in patients with malignant melanoma.

KW - Female

KW - Fluorodeoxyglucose F18/chemistry

KW - Humans

KW - Magnetic Resonance Imaging/methods

KW - Male

KW - Melanoma/diagnostic imaging

KW - Middle Aged

KW - Multimodal Imaging/methods

KW - Neoplasm Metastasis

KW - Positron Emission Tomography Computed Tomography/methods

KW - Positron-Emission Tomography/methods

KW - Prospective Studies

KW - Radiopharmaceuticals/chemistry

KW - Whole Body Imaging/methods

UR - http://www.scopus.com/inward/record.url?scp=85069944015&partnerID=8YFLogxK

U2 - 10.1007/s11307-019-01413-7

DO - 10.1007/s11307-019-01413-7

M3 - Journal article

C2 - 31363965

SN - 1536-1632

VL - 22

SP - 739

EP - 744

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

IS - 3

ER -

Whole-Body [18F]FDG-PET/MRI vs. [18F]FDG-PET/CT in Malignant Melanoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this